ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study

C Ceconi, KM Fox, WJ Remme, ML Simoons, JW Deckers, M Bertrand, G Parrinello, C Kluft, Andrew Blann, D Cokkinos, R Ferrari

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-alpha), and a biomarker of thrombosis, D-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-alpha, and D-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-alpha (27.60-25.20 pg/mL; P
Original languageEnglish
Pages (from-to)273-5
Number of pages3
JournalAtherosclerosis
Volume204
Issue number1
DOIs
Publication statusPublished - 1 May 2009

Fingerprint

Dive into the research topics of 'ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study'. Together they form a unique fingerprint.

Cite this